


REMARKS

This Preliminary Amendment is being made upon entry of International Application No. PCT/US03/009461 into the U.S. National Phase of prosecution.

In the specification, a new paragraph has been added to the first line of the specification to include the priority information. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b).

Claims 52-57 have been cancelled without prejudice or disclaimer. Claims 3-18, 20-21, 27, 31-38, 40-44, 46-51 and 58 have been amended to comply with U.S. practice.

Respectfully submitted,




Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090

N:\KLS\Cases\PS1327P\Natl Stage\preliminary amendment.doc

ABSTRACT OF THE DISCLOSURE

Disclosed is a compound having the formula



pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.